Overview
This article appeared in The Newtonian, Issue #41, Autumn 2026
Obviousness-type double patenting (ODP) is a judicially created doctrine, grounded in 35 U.S.C. § 101’s reference to “a patent,” barring an applicant from obtaining a second patent on an invention not patentably distinct from one already claimed. Its historically dominant rationale was preventing an unjustified timewise extension of patent exclusivity, which is why ODP can be overcome by filing a terminal disclaimer. To overcome ODP, a terminal disclaimer must tie both the expiration date and the ownership of the challenged patent or application to the reference patent.
The shift to a 20-year-from-filing patent term diluted the term-extension concern of ODP considerably: patents sharing a priority date ordinarily expire on the same day. Two recent Federal Circuit decisions have defined the space that remains.
In In re Cellect, LLC (Fed. Cir. 2023), the Federal Circuit affirmed a United States Patent and Trademark Office (USPTO) ODP rejection and held that where a patent has received patent term adjustment (PTA), the ODP analysis considers the expiration date after PTA is added, distinguishing PTA from patent term extension (PTE), which Novartis AG v. Ezra Ventures LLC (Fed. Cir. 2018) had excluded from the ODP analysis. Cellect’s patents all shared a priority date and had different expiration dates solely because of differing PTA grants. One patent in the family received no PTA and was limited to its 20-year statutory term. The Federal Circuit held that PTA in the other family members constituted an inappropriate timewise extension of patent term of the challenged patents. The Federal Circuit also agreed with the USPTO that a risk of separate ownership existed and that a terminal disclaimer would have been required to ensure common ownership, observing memorably that “promises do not substitute for sound applications of rules of law.”
Allergan USA, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2024) then limited the reach of Cellect. In Allergan, the first-filed, first-issued patent had received 467 days of PTA and therefore outlived two later-filed continuations sharing its priority date. Reversing an ODP invalidation, the Federal Circuit reasoned that ODP exists to prevent a second patent from extending the life of a first, and held “that a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date” because the first-filed, first-issued patent in a family “sets the maximum period of exclusivity for the claimed subject matter and any patentably indistinct variants.”
Ex parte Baurin’s Initial Decision: The PTAB Expands Allergan
In Baurin, the examiner issued six ODP rejections of Baurin’s application over commonly owned patents and co-pending applications, each with a later patent term filing date than the rejected application. Additionally, the rejected application was already limited to its 20-year patent term because of previously filed terminal disclaimers. The examiner acknowledged that the rejected application would not have a timewise extension of term over the reference patents and applications but invoked the risk of divided ownership as supporting the need for a terminal disclaimer. Baurin appealed. Two points were undisputed throughout the appeal: the rejected claims would have been obvious over the claims of the reference patent, and the claims of the reference patent were not obvious over the disclosure of the rejected application, as published, and could not have been presented in that application.
The Patent Trial and Appeal Board (PTAB) reversed all six rejections. Even though the rejected application and the reference patent were not in the same family and, thus, did not share a priority date, the PTAB found Allergan’s reasoning compelling and extended Allergan’s holding to the appealed ODP rejections. The PTAB held the appealed claims “would be a first patent” to the claimed construct, not “a second, later expiring patent for the same invention,” and therefore that the claims of the reference patent could not serve as reference claims. It disposed of the examiner’s common ownership concern in a footnote: a risk of separate ownership “is immaterial where the [reference] patent is not a proper nonstatutory double patenting reference.”
Rehearing Sets Up the Anti-Harassment Question
The examiner requested rehearing of the PTAB decision, arguing that the panel had misapprehended Allergan and that the risk of separate ownership was an independent basis for the rejections, citing to In re Fallaux (Fed. Cir. 2009). In Fallaux the reference patents had later patent term filing dates and later expiration dates than the rejected application, and the Fallaux court frankly acknowledged that “the unjustified patent term extension justification for obviousness-type double patenting has limited force in this case.” It nonetheless affirmed the USPTO’s rejection, turning to “a second justification for obviousness-type double patenting, harassment by multiple assignees.” That justification was “particularly pertinent” because the Fallaux applicant had, by assignment, divided ownership between different entities, rendering terminal disclaimer impossible, a defect the Fallaux court noted “was of the applicant’s creation.”
The PTAB was unmoved; it denied rehearing, reasoning that Fallaux presented only the question whether the one-way or two-way ODP test applied, and no party in Fallaux disputed whether the reference patents were proper references. Because the anti-harassment statement was unnecessary to resolve the Fallaux dispute, it was “dicta at best,” and, quoting In re Van Ornum (C.C.P.A. 1982), “[p]recedents are of value for what they decide, not for every sentence they contain.” The PTAB further concluded that no court has held separate-ownership risk to be a standalone justification for an ODP invalidation.
The ARP’s Uneasy Holding: ODP Without Timewise Extension
USPTO Director John Squires sua sponte convened an Appeals Review Panel (ARP) to consider the Baurin appeal, asking: (1) whether Allergan applies to the Baurin appeal and what constitutes “first-filed” for ODP purposes under facts different from Allergan; and (2) whether the risk of separate ownership and potential harassment by separate owners provide an independent basis supporting an ODP rejection. The ARP reversed the PTAB’s decision, affirmed the examiner’s ODP rejections, and designated the decision precedential.
Regarding the first question, the ARP held that Allergan does not apply. Reading “first-filed” as referring to actual filing dates and “common priority date” as referring to patent term filing dates, the ARP found all three prongs unsatisfied: the rejected application is not the first actual filing in its family, is not “first-issued” because it remains pending, and shares no patent term filing date with the reference patent.
Regarding the second question, the ARP held that improper term extension is not the only rationale underpinning the ODP doctrine. Relying on Fallaux and In re Hubbell (Fed. Cir. 2013), cases in which, the ARP emphasized, no term-extension concern was apparent, yet the rejections were affirmed, it held the PTAB erred in dismissing the anti-harassment rationale as immaterial and its supporting authority as dicta. To treat that discussion as dicta, the ARP reasoned, would mean the rejections were affirmed for no underlying rationale at all. Under binding precedent, the ARP indicated that it was “compelled” to sustain the rejections.
Remarkably, the ARP said it would rule otherwise if it could. “Were the Office not bound by the Federal Circuit’s precedents,” it wrote, it “would clarify that the risk of separate ownership and hypothetical harassment generally should not form a standalone basis for OTDP rejections during examination,” because absent evidence of actual ownership splitting the Office “is just speculating.” It offered a hypothetical, an inventor departing Acme Corp. to found Beta Corp., whose nonobvious improvement patent issues first, to illustrate a “trap” with no viable escape. The ARP expressly invited the Federal Circuit to clarify the continued role of the anti-harassment rationale for ODP, noting that the issue is presently before the court in In re Ablynx N.V.
In re Ablynx: Same ODP Theory, Higher Court
The ARP pointed the Federal Circuit directly at the ongoing appeal in In re Ablynx N.V. (Fed. Cir. No. 26-1333, appeal from Ex parte Baumeister), where a different PTAB panel affirmed an examiner’s ODP rejections over six later-filed, later-expiring reference patents. The same undisputed facts apply: (a) as a result of a terminal disclaimer, the rejected application could not have a later expiration date than any reference patent; and (b) the reference patents all covered nonobvious improvements over the rejected application. In affirming the examiner’s ODP rejections based on an anti-harassment rationale, the PTAB in Ablynx held that Fallaux was “directly on point,” “binding,” and “good law.”
On appeal, Ablynx argues that, on the undisputed facts, no timewise extension of the patent term is possible and that Federal Circuit caselaw makes clear that preventing an unjust timewise extension of exclusivity is “the fundamental purpose of the ODP doctrine.” Ablynx argues that the Federal Circuit has found no ODP when that fundamental purpose was not violated. Regarding the anti-harassment rationale, Ablynx argues that the PTAB’s reliance in Fallaux is misplaced because Fallaux did not address, let alone decide, whether a later-filed, later-expiring patent may serve as an ODP reference against an earlier-filed application.
The USPTO’s response brief echoed the Baurin ARP decision’s statement that it was “compelled” to affirm the ODP rejection, arguing that the PTAB in Ablynx properly applied binding precedent in applying the anti-harassment rationale to affirm the examiner’s ODP rejections. The USPTO further argues that Ablynx “had not identified any legal authority rejecting the anti-harassment rationale as a sole basis for an ODP rejection” and contends that the “no ODP” cases cited by Ablynx were distinguishable on the facts.
Ablynx’s reply, filed after the ARP decision in Baurin issued, leans on the ARP’s own words. Specifically, Ablynx highlights the ARP’s statement that, absent Federal Circuit precedent, “the risk of separate ownership and hypothetical harassment generally should not form a standalone basis for OTDP rejections” and notes the agency “has invited clarification from this Court in this appeal.” Ablynx pointed out that it faces precisely the trap the ARP hypothetically described: certain reference patents are co-owned with Merck Patent GmbH, so a common-ownership disclaimer would render any issued patent unenforceable.
The Ablynx appeal is still ongoing, and the Federal Circuit has not yet issued its decision.
What this means, and practical takeaways
Until the Federal Circuit weighs in, examiners may sustain ODP rejections even where no patent term extension is possible, and the precedential designation means they likely will. The ARP’s guidance confines Allergan narrowly: pre-Allergan MPEP § 804 practice governs unless the application and reference share a family and patent term filing date and the claims under examination are first-filed, first-issued, and later-expiring, a combination that “will rarely, if ever, arise in original examination” and will likely be limited to reissues and re-examinations.
- Allergan will rarely be available. Do not assume an earlier patent term filing date is a defense. Argue Allergan where the facts genuinely fit; preserve the purposive argument for appeal.
- Map ownership before filing. Joint-development and inventor-mobility scenarios are exactly where ODP becomes a trap.
- File foundational claims early. The ARP held that it was “bound” by Fallaux. Under Fallaux, the two-way test was unavailable in Baurin because the rejected application was a continuation, so the Office was not responsible for any delay.
- Watch expiration mechanics. PTA counts in the ODP analysis; PTE does not; terminal disclaimers can truncate PTA.
- Preserve the issue. Where possible, try to get the examiner to acknowledge on the record that the reference claims are nonobvious over the rejected application’s disclosure and could not have been presented in it.